Orforglipron Capsules: molecular data, studies & sources

Orforglipron Capsules is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked 2026-10-09 · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF): C48H48F2N10O5
Molecular weight (MW): 883.0 g/mol
PubChem compound ID: 137319706
Record title: Orforglipron

Capsule listings contain orforglipron with excipients; the structure describes the active compound only.

Source: PubChem CID 137319706 · retrieved 2026-10-09

2D molecular structure for Orforglipron Capsules, PubChem CID 137319706 — 2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.

Chemical identifiers and source data

IUPAC name: 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one
InChIKey: USUWIEBBBWHKNI-KHIFEHGGSA-N
SMILES: C[C@H]1C[C@]1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)[C@H]5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7[C@@H]6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C

Machine-readable PubChem source

Identifiers

PubChem CID: 137319706
CAS Registry Number: 2212020-52-3via EPA DSSTox
ChEMBL ID: CHEMBL4446782
InChIKey: USUWIEBBBWHKNI-KHIFEHGGSA-N
Wikidata: Q120491908

Other names and development codes: LY-3502970

CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-09.

Calculated molecular descriptors

Monoisotopic (exact) mass	882.3777 Da
Heavy atoms	65
Hydrogen-bond donors	1
Hydrogen-bond acceptors	8
Rotatable bonds	7
Topological polar surface area	155.9 Å²
Calculated logP (Crippen)	7.44
Rings	11
Stereocenters	4
Formal charge	0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

US regulatory status & drug development

Drug development record (ChEMBL)

Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.

ChEMBL ID: CHEMBL4446782
Modality: Small molecule
Highest clinical stage: Phase 3
Record name: ORFORGLIPRON

Synonyms, codes and trade names

Synonyms and development codes: LY-3502970 · LY3502970 · Orforglipron

Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL4446782 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-09

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Orforglipron as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

40 registered studies matched, 20 currently active or recruiting, 15 with results posted on ClinicalTrials.gov.

By highest phase: Phase 4 · 2Phase 3 · 27Phase 1 · 11
By registry status: Completed · 20Active Not Recruiting · 8Recruiting · 8Not Yet Recruiting · 4

Study	Phase · status	Conditions	Sponsor · size
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNCT07790861 · start 2026-12 · primary completion 2028-03	Phase 3Not Yet Recruiting	Obesity · Overweight	Eli Lilly and Company192 participants
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationNCT07729332 · start 2026-11-01 · primary completion 2031-07-31	Phase 4Not Yet Recruiting	Obesity	Massachusetts General Hospital60 participants
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesNCT07739537 · start 2026-10-01 · primary completion 2029-09-30	Phase 4Not Yet Recruiting	Diabete Type 2 · Pharmacogenomic Drug Interaction	Massachusetts General Hospital100 participants
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336 · start 2026-09 · primary completion 2030-03	Phase 3Not Yet Recruiting	Diabetes Mellitus, Type 2	Eli Lilly and Company170 participants
IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsNCT07793019 · start 2026-09-07 · primary completion 2027-09-06	Phase 1Recruiting	Overweight · Healthy Participants · Obesity	Innovent Biologics (Suzhou) Co. Ltd.104 participants
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · start 2026-08-26 · primary completion 2029-08	Phase 3Recruiting	Overweight · Prediabetic State · Prehypertension · Obesity, Abdominal	Eli Lilly and Company2001 participants
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307 · start 2026-07-15 · primary completion 2027-05	Phase 3Recruiting	Diabetes Mellitus, Type 2 · Diabetes Melletus · Glucose Metabolism Disorders · Metabolic Disorders · Nutritional and Metabolic Diseases · Endocrine System Diseases	Eli Lilly and Company130 participants
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390 · start 2025-12-01 · primary completion 2031-08	Phase 3Recruiting	Atherosclerosis Cardiovascular Disease · Chronic Kidney Disease	Eli Lilly and Company7140 participants
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseNCT07223593 · start 2025-10-31 · primary completion 2028-06	Phase 3Recruiting	Peripheral Arterial Disease	Eli Lilly and Company1205 participants
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471 · start 2025-09-15 · primary completion 2028-04	Phase 3Active Not Recruiting	Osteoarthritis	Eli Lilly and Company800 participants

Show 30 more registered studies

Study	Phase · status	Conditions	Sponsor · size
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884 · start 2025-09-30 · primary completion 2028-03	Phase 3Recruiting	Urinary Incontinence,Stress	Eli Lilly and Company1000 participants
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459 · start 2025-05-15 · primary completion 2027-08	Phase 3Active Not Recruiting	Obesity · Overweight	Eli Lilly and Company800 participants
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472 · start 2025-05-19 · primary completion 2027-08	Phase 3Active Not Recruiting	Obesity · Overweight · Type 2 Diabetes	Eli Lilly and Company600 participants
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792 · start 2025-05-15 · primary completion 2027-08	Phase 3Active Not Recruiting	Obesity · Overweight · Type 2 Diabetes	Eli Lilly and Company1400 participants
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · start 2025-04-30 · primary completion 2027-09	Phase 3Active Not Recruiting	Hypertension	Eli Lilly and Company974 participants
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · start 2025-04-30 · primary completion 2027-09	Phase 3Active Not Recruiting	Hypertension · Overweight or Obesity	Eli Lilly and Company487 participants
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530 · start 2025-04-30 · primary completion 2027-09	Phase 3Active Not Recruiting	Hypertension	Eli Lilly and Company487 participants
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549 · start 2024-11-18 · primary completion 2027-02	Phase 3Recruiting	Obesity · Overweight	Eli Lilly and Company125 participants
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939 · start 2024-11-18 · primary completion 2027-12	Phase 3Recruiting	Obesity · Overweight	Eli Lilly and Company150 participants
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · start 2023-06-05 · primary completion 2025-07-25	Phase 3Active Not RecruitingResults posted 2026-08-14	Obesity · Overweight · Overweight or Obesity	Eli Lilly and Company3127 participants
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or OverweightNCT06824051 · start 2025-02-17 · primary completion 2026-01-26	Phase 1Completed	Obesity · Overweight	Eli Lilly and Company120 participants
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy ParticipantsNCT06692348 · start 2024-12-13 · primary completion 2025-06-09	Phase 1Completed	Healthy	Eli Lilly and Company86 participants
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy ParticipantsNCT06704763 · start 2024-12-06 · primary completion 2025-02-05	Phase 1CompletedResults posted 2026-05-26	Healthy	Eli Lilly and Company27 participants
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · start 2024-10-22 · primary completion 2026-07-21	Phase 3Completed	OSA · Overweight or Obesity	Eli Lilly and Company712 participants
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916 · start 2024-09-13 · primary completion 2025-11-21	Phase 3Completed	Obesity · Overweight	Eli Lilly and Company376 participants
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightNCT06440980 · start 2024-06-24 · primary completion 2025-06-02	Phase 1CompletedResults posted 2026-07-17	Healthy · Obese · Overweight · Obesity	Eli Lilly and Company533 participants
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy ParticipantsNCT06370728 · start 2024-05-06 · primary completion 2024-07-23	Phase 1CompletedResults posted 2026-07-17	Healthy	Eli Lilly and Company30 participants
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsNCT06186622 · start 2024-01-02 · primary completion 2024-07-10	Phase 1CompletedResults posted 2026-05-22	Healthy · Obese · Overweight	Eli Lilly and Company50 participants
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminNCT06192108 · start 2024-01-10 · primary completion 2025-09-26	Phase 3Completed	Type 2 Diabetes	Eli Lilly and Company962 participants
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311 · start 2023-11-10 · primary completion 2025-09-15	Phase 3CompletedResults posted 2026-10-01	Type 2 Diabetes	Eli Lilly and Company546 participants
A Phase I Study of LY3502970 in Healthy ParticipantsNCT06085482 · start 2023-10-19 · primary completion 2024-01-05	Phase 1CompletedResults posted 2026-05-27	Healthy	Eli Lilly and Company10 participants
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesNCT06010004 · start 2023-09-28 · primary completion 2025-06-05	Phase 3CompletedResults posted 2026-06-30	Type 2 Diabetes	Eli Lilly and Company401 participants
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related ComorbiditiesNCT06023095 · start 2023-09-21 · primary completion 2024-07-29	Phase 1CompletedResults posted 2026-07-17	Overweight · Obesity	Eli Lilly and Company24 participants
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221 · start 2023-09-22 · primary completion 2025-08-22	Phase 3CompletedResults posted 2026-09-15	Type 2 Diabetes	Eli Lilly and Company1698 participants
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940 · start 2023-08-09 · primary completion 2025-04-03	Phase 3CompletedResults posted 2026-04-22	Type 2 Diabetes	Eli Lilly and Company559 participants
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseNCT05931380 · start 2023-07-31 · primary completion 2025-06-19	Phase 3CompletedResults posted 2026-07-20	Obesity	Eli Lilly and Company238 participants
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.NCT05936138 · start 2023-07-13 · primary completion 2024-04-11	Phase 1CompletedResults posted 2026-06-09	Renal Insufficiency · Healthy	Eli Lilly and Company24 participants
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620 · start 2023-06-05 · primary completion 2025-08-08	Phase 3CompletedResults posted 2026-09-04	Obesity · Overweight · Type 2 Diabetes	Eli Lilly and Company1613 participants
A Study of LY3502970 in Participants With Impaired and Normal Liver FunctionNCT05882032 · start 2023-06-13 · primary completion 2024-11-18	Phase 1CompletedResults posted 2026-05-27	Healthy · Hepatic Insufficiency	Eli Lilly and Company29 participants
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · start 2023-04-03 · primary completion 2026-03-16	Phase 3Completed	Type 2 Diabetes · Obesity · Overweight or Obesity · Overweight · Cardiovascular Diseases · Chronic Kidney Disease	Eli Lilly and Company2749 participants

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received Orforglipron, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

Human study · PubMed trial index Compound given to participants
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
Wharton S, Aronne LJ, Stefanski A et al. · The New England journal of medicine · 2025
PMID 40960239 · DOI: 10.1056/NEJMoa2511774 · Registration NCT05869903
Human study · PubMed trial index Compound given to participants
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
Rosenstock J, Hsia S, Nevarez Ruiz L et al. · The New England journal of medicine · 2025
PMID 40544435 · DOI: 10.1056/NEJMoa2505669 · Registration NCT05971940
Human study · PubMed trial index Compound given to participants
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Pratt E, Ma X, Liu R et al. · Diabetes, obesity & metabolism · 2023
PMID 37344954 · DOI: 10.1111/dom.15184
Human study · PubMed trial index Compound given to participants
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Pratt E, Ma X, Liu R et al. · Diabetes, obesity & metabolism · 2023
PMID 37264711 · DOI: 10.1111/dom.15150
Human study · PubMed trial index Compound given to participants
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Wharton S, Blevins T, Connery L et al. · The New England journal of medicine · 2023
PMID 37351564 · DOI: 10.1056/NEJMoa2302392
Human study · PubMed trial index Compound given to participants
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Aronne LJ, Horn DB, le Roux CW et al. · Nature medicine · 2026
PMID 42120723 · DOI: 10.1038/s41591-026-04386-7 · Registration NCT06584916

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

Research publication · design requires review
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.
Sloop KW, Cox AL, Wainscott DB et al. · Science translational medicine · 2024
PMID 39693407 · DOI: 10.1126/scitranslmed.adp5765
Research publication · design requires review
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
Kawai T, Sun B, Yoshino H et al. · Proceedings of the National Academy of Sciences of the United States of America · 2020
PMID 33177239 · DOI: 10.1073/pnas.2014879117

Orforglipron Capsules supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

Reference sources & further reading

PubChem compound record 137319706 — chemical identity and structure.
ChEMBL drug record CHEMBL4446782 — development stage, mechanism and synonyms.

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.